Holdings
Catalio Capital Management, LP
As of Jun 30, 2026, Catalio Capital Management, LP reported 36 positions worth US$504M. Largest: Avalyn Pharma Inc., Johnson & Johnson and Gilead Sciences, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Avalyn Pharma Inc. | 1.68M | US$55.2M | new | Jun 30, 2026 |
| Johnson & Johnson | 139K | US$35.3M | new | Jun 30, 2026 |
| Gilead Sciences, Inc. | 269K | US$34M | +105K | Jun 30, 2026 |
| Bridgebio Pharma, Inc. | 455K | US$33.9M | +23,027 | Jun 30, 2026 |
| Syndax Pharmaceuticals, Inc. | 1.22M | US$26.6M | +172K | Jun 30, 2026 |
| Definium Therapeutics, Inc. | 563K | US$26.5M | −475K | Jun 30, 2026 |
| Bristol-myers Squibb Company | 413K | US$23.8M | −7,766 | Jun 30, 2026 |
| Parabilis Medicines, Inc. | 824K | US$22.6M | new | Jun 30, 2026 |
| Natera, Inc. | 82,181 | US$22.3M | +11,274 | Jun 30, 2026 |
| Incyte Corporation | 192K | US$21.7M | +9,526 | Jun 30, 2026 |